These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29371384)

  • 1. RESPIRE 2: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
    Aksamit T; De Soyza A; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis.
    De Soyza A; Aksamit T; Bandel TJ; Criollo M; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Eur Respir J; 2018 Jan; 51(1):. PubMed ID: 29371383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
    Aksamit T; Bandel TJ; Criollo M; De Soyza A; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Contemp Clin Trials; 2017 Jul; 58():78-85. PubMed ID: 28495619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study.
    Wilson R; Welte T; Polverino E; De Soyza A; Greville H; O'Donnell A; Alder J; Reimnitz P; Hampel B
    Eur Respir J; 2013 May; 41(5):1107-15. PubMed ID: 23018904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
    Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ciprofloxacin Dry Powder for Inhalation (ciprofloxacin DPI): Technical design and features of an efficient drug-device combination.
    McShane PJ; Weers JG; Tarara TE; Haynes A; Durbha P; Miller DP; Mundry T; Operschall E; Elborn JS
    Pulm Pharmacol Ther; 2018 Jun; 50():72-79. PubMed ID: 29621625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial.
    Serisier DJ; Bilton D; De Soyza A; Thompson PJ; Kolbe J; Greville HW; Cipolla D; Bruinenberg P; Gonda I;
    Thorax; 2013 Sep; 68(9):812-7. PubMed ID: 23681906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
    Tran TT; Vidaillac C; Yu H; Yong VFL; Roizman D; Chandrasekaran R; Lim AYH; Low TB; Tan GL; Abisheganaden JA; Koh MS; Teo J; Chotirmall SH; Hadinoto K
    Int J Pharm; 2018 Aug; 547(1-2):368-376. PubMed ID: 29886096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microbiological changes observed over 48 weeks of treatment with inhaled liposomal ciprofloxacin in individuals with non-cystic fibrosis bronchiectasis and chronic Pseudomonas aeruginosa lung infection.
    VanDevanter DR; Gonda I; Dahms J; Cipolla D; Davis AM; Chalmers JD; Froehlich J
    Clin Microbiol Infect; 2019 Dec; 25(12):1532-1538. PubMed ID: 31035017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spotlight on inhaled ciprofloxacin and its potential in the treatment of non-cystic fibrosis bronchiectasis.
    Chorepsima S; Kechagias KS; Kalimeris G; Triarides NA; Falagas ME
    Drug Des Devel Ther; 2018; 12():4059-4066. PubMed ID: 30568427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ciprofloxacin Dry Powder for Inhalation in Patients with Non-Cystic Fibrosis Bronchiectasis or Chronic Obstructive Pulmonary Disease, and in Healthy Volunteers.
    Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Kietzig C; Weimann B
    J Aerosol Med Pulm Drug Deliv; 2017 Feb; 30(1):53-63. PubMed ID: 27448179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis.
    Bilton D; Henig N; Morrissey B; Gotfried M
    Chest; 2006 Nov; 130(5):1503-10. PubMed ID: 17099030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis.
    Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Patzlaff A; Weimann B
    J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):156-163. PubMed ID: 30848695
    [No Abstract]   [Full Text] [Related]  

  • 16. Meta-analysis of efficacy and safety of inhaled ciprofloxacin in non-cystic fibrosis bronchiectasis patients.
    Wang S; Zhang A; Yao X
    Intern Med J; 2021 Sep; 51(9):1505-1512. PubMed ID: 33469994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
    Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
    Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis.
    Dorkin HL; Staab D; Operschall E; Alder J; Criollo M
    BMJ Open Respir Res; 2015; 2(1):e000100. PubMed ID: 26688732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
    Langton Hewer SC; Smyth AR
    Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
    Konstan MW; Flume PA; Kappler M; Chiron R; Higgins M; Brockhaus F; Zhang J; Angyalosi G; He E; Geller DE
    J Cyst Fibros; 2011 Jan; 10(1):54-61. PubMed ID: 21075062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.